(HUM) Humana (publ) - Ratings and Ratios
Elderly, Family, Mental, Residential, Assisted
HUM EPS (Earnings per Share)
HUM Revenue
Description: HUM Humana (publ)
Humana AB (publ) is a leading provider of care services in the Nordic region, operating in Sweden, Finland, Norway, and Denmark. The companys comprehensive range of services includes individual and family care, elderly care, and specialized housing for individuals with functional impairments, mental illness, and substance abuse problems. With a strong presence in the region, Humana has established itself as a key player in the healthcare services sector.
From a business perspective, Humanas diversified service portfolio and geographic presence provide a stable foundation for growth. The companys focus on providing high-quality care services, combined with its ability to adapt to changing regulatory environments, positions it well for long-term success. Additionally, the Nordic regions emphasis on social welfare and healthcare services creates a favorable operating environment for Humana.
Analyzing the available data, we can observe that Humanas stock has experienced fluctuations in recent times. The current price of 36.50 SEK is below its 20-day and 50-day simple moving averages (SMA20: 36.79, SMA50: 38.91), indicating a potential downward trend. However, the stock is above its 200-day moving average (SMA200: 37.28), suggesting some underlying stability. The average true range (ATR) of 1.07, representing a 2.93% daily price movement, indicates moderate volatility.
Using the available technical and fundamental data, we can forecast Humanas stock performance. Given the current price-earnings ratio (P/E) of 12.63 and return on equity (RoE) of 6.31, we can expect a relatively stable performance in the short term. However, the stocks current price being below its 52-week high (46.37) and above its 52-week low (28.54) suggests potential for recovery. If the company can maintain its current growth trajectory and improve its profitability, we can expect the stock to appreciate in value, potentially reaching 40-42 SEK in the next 6-12 months, representing a 10-15% increase from current levels.
Additional Sources for HUM Stock
HUM Stock Overview
Market Cap in USD | 196m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception |
HUM Stock Ratings
Growth Rating | -16.9 |
Fundamental | 32.6 |
Dividend Rating | 17.6 |
Rel. Strength | 20.7 |
Analysts | - |
Fair Price Momentum | 33.23 SEK |
Fair Price DCF | 283.10 SEK |
HUM Dividends
Dividend Yield 12m | 2.75% |
Yield on Cost 5y | 2.08% |
Annual Growth 5y | % |
Payout Consistency | 25.6% |
Payout Ratio | 25.5% |
HUM Growth Ratios
Growth Correlation 3m | -60.8% |
Growth Correlation 12m | 72.9% |
Growth Correlation 5y | -70.2% |
CAGR 5y | -5.18% |
CAGR/Max DD 5y | -0.06 |
Sharpe Ratio 12m | -0.13 |
Alpha | 0.21 |
Beta | 0.784 |
Volatility | 34.34% |
Current Volume | 207.9k |
Average Volume 20d | 58.8k |
Stop Loss | 35.6 (-3.1%) |
As of July 16, 2025, the stock is trading at SEK 36.75 with a total of 207,900 shares traded.
Over the past week, the price has changed by +1.36%, over one month by +1.36%, over three months by -15.00% and over the past year by +10.19%.
Neither. Based on ValueRay´s Fundamental Analyses, Humana (publ) is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.57 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HUM is around 33.23 SEK . This means that HUM is currently overvalued and has a potential downside of -9.58%.
Humana (publ) has no consensus analysts rating.
According to our own proprietary Forecast Model, HUM Humana (publ) will be worth about 36.2 in July 2026. The stock is currently trading at 36.75. This means that the stock has a potential downside of -1.41%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 48 | 30.6% |
Analysts Target Price | - | - |
ValueRay Target Price | 36.2 | -1.4% |